Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.35 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.31 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.31 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 5/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075947 | 0.97 | CA12 (0.45) | CA12CA1CA9IDO1RAPGEF4 | |
| Hydrochloric Acid SCHEMBL670927 | 0.83 | RAPGEF4 (0.47) | IDO1RAPGEF4CYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL22289295 | 0.83 | IDO1 (0.31) | IDO1 | |
| SCHEMBL18593306 | 0.79 | RAPGEF4 (0.47) | CA12CA1CA9RAPGEF4CYP1A2 | |
| SCHEMBL360242 | 0.79 | RAPGEF4 (0.48) | IDO1RAPGEF4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31373114 | 0.79 | HTR2B (0.39) | CA12CA1CA9MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL20984864 | 0.78 | NQO2 (0.39) | MEN1ALDH1A1RAB9AKMT2AMAOA | |
| SCHEMBL997922 | 0.76 | HDAC3 (0.42) | IDO1RAPGEF4ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL16876690 | 0.74 | RAPGEF4 (0.40) | CA12CA1IDO1RAPGEF4TDP1 | |
| SCHEMBL24728554 | 0.74 | CYP4F2 (0.41) | CA12CA1CA9IDO1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425464-A1 | Substituted Monohydrazides as Potent Antifungal Agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2024-12-26 | — | — | US | disclosed |
| CN-113226321-B | Pyrazolyl compounds and methods of use thereof | 阿利安制药有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240270743-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3160981-B1 | FUSED TRITERPENE COMPOUNDS AND USES THEREOF | PIRAMAL ENTPR LTD (IN) | 2024-01-24 | — | — | EP | disclosed |
| US-11851391-B2 | Antifungal compounds and methods of forming the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023018682-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-113234063-B | Pyrazolyl-asarum derivative, preparation method and application thereof | 宁夏师范学院 | 2022-11-25 | — | — | CN | disclosed |
| CN-107793362-B | Synthesis and application of phenyl pyridazinone derivative | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2008015415-A2 | ASYMMETRIC FLUORO-SUBSTITUTED POLYMETHINE DYES | GE HEALTHCARE AS (NO) | 2008-02-07 | — | — | WO | disclosed |
| US-20080027122-A1 | Indole derivatives | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| EP-1874871-A1 | WATER SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE Healthcare UK Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006129178-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060239922-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| WO-2006111726-A1 | WATER SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | GE HEALTHCARE UK LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | PTGS2 56/4885MAOA 2834/4885MAOB 2294/4885 |
| US-20080027122-A1 | Indole derivatives | SLC5A1, SLC5A2, SLC5A11 | PTGS2 3199/4885MAOA 654/4885MAOB 550/4885 |
| US-20240270743-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | NLRP1, NLRP3, EPX | PTGS2 1125/4885MAOA 3490/4885MAOB 4190/4885 |
| US-20060239922-A1 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS | TPD52L2, MRPL21, MRPL9 | PTGS2 4844/4885MAOA 2718/4885MAOB 2096/4885 |
| US-20240425464-A1 | Substituted Monohydrazides as Potent Antifungal Agents | ERG28, DPM1, MANBA | PTGS2 4475/4885MAOA 726/4885MAOB 651/4885 |
| US-11851391-B2 | Antifungal compounds and methods of forming the same | DPM1, ERG28, SUCLG1 | PTGS2 2635/4885MAOA 628/4885MAOB 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.